In fact, HHT animal models indicate that VEGF inhibition can partially reverse AVM pathology (24–26), and bevacizumab, a VEGF-A monoclonal neutralizing antibody, provides therapeutic benefit for patients with HHT (27, 28). This evidence concerns the gene VEGFA and hereditary hemorrhagic telangiectasia.